The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | What are the benefits of having different chronic lymphocytic leukemia (CLL) treatment options?
Barbara Eichhorst, MD, from the University of Cologne, Cologne, Germany, discusses the advantages of having many treatment options in chronic lymphocytic leukemia (CLL) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She explains that even for high-risk CLL patients a number of therapies are available. Dr Eichhorst speaks about what can be done if patients do not tolerate a particular treatment, and clinical trials of combination therapies and checkpoint inhibitors. However, Dr Eichhorst argues that if patients transform to diffuse large B-cell lymphoma, this is still difficult to treat, and highlights the need for novel agents for treating this disease.
